Immunic Historical Cash Flow
| IMUX Stock | USD 1.18 0.09 7.09% |
Analysis of Immunic cash flow over time is an excellent tool to project Immunic future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 60.1 M or Depreciation of 105.5 K as it is a great indicator of Immunic ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Immunic latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Immunic is a good buy for the upcoming year.
Immunic |
About Immunic Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Immunic balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Immunic's non-liquid assets can be easily converted into cash.
Immunic Cash Flow Chart
Immunic Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Immunic Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Immunic's Change In Working Capital is fairly stable compared to the past year. Capital Expenditures is likely to rise to about 496.2 K in 2024, despite the fact that Change In Cash is likely to grow to (57.1 M). Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Immunic to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Immunic operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Immunic's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Immunic current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.At this time, Immunic's Change In Working Capital is fairly stable compared to the past year. Capital Expenditures is likely to rise to about 496.2 K in 2024, despite the fact that Change In Cash is likely to grow to (57.1 M).
Immunic cash flow statement Correlations
Click cells to compare fundamentals
Immunic Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Immunic cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 16.3M | 98.1M | (40.6M) | 19.9M | (60.1M) | (57.1M) | |
| Stock Based Compensation | 6.5M | 2.7M | 5.9M | 7.9M | 7.1M | 4.4M | |
| Free Cash Flow | (28.6M) | (46.3M) | (83.3M) | (65.3M) | (71.2M) | (67.6M) | |
| Change In Working Capital | (1.4M) | (2.4M) | (9.3M) | 9.5M | 15.0M | 15.8M | |
| Begin Period Cash Flow | 13.1M | 29.4M | 127.5M | 86.9M | 106.7M | 60.1M | |
| Other Cashflows From Financing Activities | (270K) | (146K) | (67K) | 5K | (129K) | (122.6K) | |
| Depreciation | 50K | 39K | 85K | 77K | 111K | 105.5K | |
| Other Non Cash Items | 1.5M | (2.5M) | 8.6M | 37.7M | 1.3M | 1.3M | |
| Capital Expenditures | 55K | 146K | 67K | 112K | 334K | 496.2K | |
| Total Cash From Operating Activities | (28.5M) | (46.1M) | (83.2M) | (65.1M) | (70.8M) | (67.3M) | |
| Net Income | (34.9M) | (44.0M) | (92.9M) | (120.4M) | (93.6M) | (88.9M) | |
| Total Cash From Financing Activities | 34.9M | 144.4M | 42.8M | 95.8M | 1.0M | 981.3K | |
| End Period Cash Flow | 29.4M | 127.5M | 86.9M | 106.7M | 46.7M | 64.0M | |
| Sale Purchase Of Stock | 34.9M | 144.4M | 92K | 182K | 129K | 122.6K | |
| Total Cashflows From Investing Activities | 10.5M | (146K) | (67K) | (9.7M) | (8.8M) | (8.3M) | |
| Cash And Cash Equivalents Changes | 16.9M | 98.2M | (40.5M) | 20.9M | 24.0M | 25.2M | |
| Cash Flows Other Operating | (2.2M) | (2.8M) | (12.8M) | 7.5M | 6.7M | 7.1M | |
| Change To Netincome | 7.7M | 219K | 18.9M | 45.7M | 52.5M | 55.1M | |
| Change To Liabilities | 865K | 414K | 3.5M | 2.0M | 2.3M | 2.5M | |
| Investments | 10.5M | (146K) | (67K) | (9.7M) | 9.5M | 9.9M | |
| Change To Operating Activities | (897K) | (3.4M) | (9.5M) | 8.7M | 10.0M | 10.5M | |
| Issuance Of Capital Stock | 35.2M | 144.4M | 42.7M | 95.6M | 853K | 810.4K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunic. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.